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IL-2–mediated apoptosis of kidney tubular epithelial cells is
regulated by the caspase-8 inhibitor c-FLIP.
Background. Tubular epithelial cells (TECs) are essential in
the maintenance of kidney function. Apoptosis of TECs oc-
cur during acute and chronic renal allograft rejection as well
as other forms of renal injury, including autoimmune nephritis.
The regulation of TEC apoptosis by proinflammatory cytokines
associated with renal inflammation [e.g., interleukin (IL)-2 and
interferon-gamma (IFN-c)] has not been extensively investi-
gated.
Methods. Apoptosis in murine TECs was determined by
FACS with annexin-V or ligation-mediated-polymerase chain
reaction (LM-PCR) and mRNA levels by reverse transcription
(RT)-PCR or Northern blot. Protein expression was observed
using Western blot.
Results. IL-2R (CD25) was expressed by murine TECs and
up-regulated by IL-2. Both IL-2 and IFN-c induced TEC
apoptosis and activated caspase-8. Apoptosis with IL-2 was
concentration-dependent and blocked by z-IETD-fmk, a spe-
cific caspase-8 inhibitor. Apoptosis with IFN-c was associated
with increased surface expression of Fas, while IL-2 had no ef-
fect on Fas. IL-2 did not induce apoptosis in Fas-deficient TECs
(M3.1-lpr) suggesting IL-2 regulation of caspase-8 activity re-
quires Fas. Consistent with this, IL-2 but not IFN-c was found to
decrease mRNA and protein expression of c-FLIP, an endoge-
nous caspase-8 inhibitor in murine TECs. Overexpression of
c-FLIP in TECs (CS3.7-FLIP) blocked apoptosis and caspase-
8 activation with both IFN-c and IL-2. c-FLIP expression was
found in kidney cortex, primary and cloned TECs, suggesting c-
FLIP is likely a key regulator of caspase-8–mediated apoptosis
in vivo.
Conclusion. This is the first report of c-FLIP regulation by
IL-2 in renal TECs. Augmentation of c-FLIP in TECs may en-
hance an endogenous mechanism by which TECs normally re-
sist injury to caspase-8–mediated apoptosis and thus may be a
useful and novel strategy to prevent tubular injury in transplant
rejection and autoimmune nephritis.
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Tubular epithelial cells (TECs) comprise the majority
of renal parenchymal cells. Their susceptibility to injury
impacts on renal function as tubular injury can be a pri-
mary cause for nephron loss [1]. Kidney cell death occurs
by apoptosis or programmed cell death and necrosis (for
review, see [2–4]), which have considerable overlap in
etiologies and pathways [4]. Apoptosis is initiated by a
variety of stimuli, including growth factor withdrawal,
physical factors, and death receptor signals. The pro-
cess is efficient and usually induces minimal inflamma-
tion. Apoptosis is frequently observed in renal injury,
including ischemia [5], cisplatinum toxicity [6], protein-
uria [6], obstruction [7], systemic sclerosis [8], calcineurin
inhibitor toxicity [9], and allograft rejection (for review,
see [2]). The short half-life of apoptotic cells in kidneys,
however, can make the process inconspicuous [2]. While
apoptosis is required for kidney remodeling and repair,
excessive cell death can lead to loss of function or in the
case of transplants, premature graft failure.
There is a growing subfamily of death receptors which
belong to the tumor necrosis factor (TNF)/nerve growth
factor receptor superfamily. CD95 (APO-1/Fas) is per-
haps the best characterized in renal injury. Fas is highly
expressed on many parenchymal cells, including tubu-
lar epithelium, and is up-regulated by cytokines such as
interferon-gamma (IFN-c). Other members of this family
(TNF-R1, DR3, TRAIL-R1, TRAIL-R2, and DR6) [10]
could also have important roles in renal injury as they
share intracellular signaling pathways. Death receptors
of this family are characterized by extracellular domain
homology and a cytoplasmic death domain. Both
receptor-related and receptor-independent apoptosis are
mediated by members of the caspase family, a series
of highly regulated intracellular cysteine proteases [11]
which can be blocked by variably specific synthetic
peptides such as YVAD, DEVD, IETD, and zVAD
[12]. Binding to Fas promotes receptor oligomerization
(trimerization) and cytoplasmic recruitment of several
adaptor proteins and procaspases to a receptor complex,
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death-inducing signaling complex (DISC) [13]. The Fas
receptor DISC includes a Fas-associated death domain
(FADD), an adaptor protein that contains a death do-
main that allows interaction with the death domain in
death receptors, and a “death effector domain” (DED)
that allows it to interact with DED domain-containing
procaspase-8. In the DISC, a high concentration of
procaspase-8 leads to self processing of the mature en-
zyme (caspase-8) which then cleaves downstream cas-
pases [3, 6, 7]. On the molecular level, the apoptotic
death program can be divided into three parts: initia-
tion, execution, and termination. In most cases the execu-
tion phase is characterized by membrane inversion and
exposure of phosphatidylserine, blebbing (zeiosis), dis-
sipation of the mitochondrial transmembrane potential
gradient, release of proteins such as cytochrome c and
apoptosis inducing factor (AIF), fragmentation of the nu-
cleus, chromatin condensation, and DNA degradation. In
the termination phase, “apoptotic bodies” are engulfed
by phagocytes [10]. The process is efficient and usually in-
duces minimal inflammation, which would be important
for efficient kidney repair and remodeling.
In previous work, we have demonstrated that the in-
duction of TEC apoptosis by IFN-c and TNF-a is depen-
dent on Fas/FasL expression which allows a cell contact
form of tubular self-injury or “fratricide” [14]. Given the
serious consequences of indiscriminant binding to death
receptors such as Fas, TECs must possess mechanisms
of self-protection as they express both Fas and its lig-
and FasL. Furthermore, as Fas-mediated death utilizes
caspase-8 activation, TECs must possess capacity to reg-
ulate potentially lethal caspase activity. c-FLIP is a major
endogenous inhibitor of caspase-8, and has been shown
to alter resistance of human renal carcinoma cells to
chemotherapeutic-induced apoptosis [15]. In the present
study, we demonstrate for the first time that both pri-
mary culture and cloned TECs express c-FLIP, suggest-
ing c-FLIP is likely used by normal TECs for protection
from apoptosis. We also show that interleukin (IL)-2 re-
ceptors expressed by TECs are up-regulated by IL-2 and
we present the novel observation that IL-2 induces apop-
tosis in TECs through inhibition of endogenous c-FLIP
likely by allowing Fas activation of caspase-8 rather than
a direct effect on caspase-8 itself. These data suggest that
augmentation of c-FLIP may enhance an endogenous
mechanism used by TECs to resist injury to caspase-8–
mediated apoptosis and thus may be a useful and novel
strategy to prevent tubular injury during diverse forms of
renal inflammation.
METHODS
Cells and reagents
Primary cultures of TECs were isolated and char-
acterized from wild-type C3H-HeJ (H-2k) using meth-
ods described previously [16]. Mice were handled in ac-
cordance with the Canadian Council on Animal Care
Guidelines under protocols approved by the Animal Use
Subcommittee at our institution. Cloned and immortal-
ized TECs (H-2k) were obtained using origin defective
SV40 DNA as described from C3H-HeJ (CS3.7) mice
and were used as well as primary cells in experiments
as indicated in results. CS3.7 TECs are highly differen-
tiated proximal tubular cells [17]. M3.1-lpr TECs were
similarly derived using Fas-deficient MRL-lpr mice and
cloned and immortalized as above. All TECs were grown
in complete K1 culture medium [Dulbecco’s modified Ea-
gle’s medium (DMEM):Hams F12] (50:50) (Invitrogen-
Gibco, Carlsbad, CA, USA), supplemented with 5%
bovine calf serum, hormone mix [5 lg/mL insulin, 1.25
ng/mL prostaglandin E1 (PGE1), 34 pg/mL triiodothy-
ronine, 5 lg/mL transferrin, 1.73 ng/mL sodium selenite,
and 18 ng/mL of hydrocortisone) and 25 ng/mL epider-
mal growth factor (EGF). Cells were grown and passaged
on 100 mm plastic tissue culture plates (Sarstedt, Inc.,
Newton, NC, USA) and removed by brief trypsiniza-
tion. Media were replaced in confluent monolayer cul-
tures before experiments with K1 media without serum
or growth factors to arrest cell division. TECs were
cultured for up to 24 hours during apoptosis assays.
Recombinant mouse IFN-c and TNF-a, anti-Fas anti-
body (Jo2 clone, for induction of apoptosis and FACS
analysis) and anti-CD25 (7D4 clone, murine high-affinity
IL-2R) were purchased from BD PharMingen (Mis-
sissauga, Ontario, Canada). Recombinant mouse IL-2
was purchased from R&D Systems (Minneapolis, MN,
USA). Rabbit anti-Fas (M20) and anti-FasL (C178)
IgG for Western blot analyses were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-c-FLIP
polyclonal antibody was obtained from Stressgen Biotech
(Victoria, British Columbia, Canada). Specific primer
sequences for reverse transcription-polymerase chain
reaction (RT-PCR) were designed using MacVector 6.5
software (Accelrys, San Diego, CA, USA), for murine
IL-2R and control glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) mRNA: IL-2Ra chain (584 bp) sense
5′-CAG CCT GGT CTA CAA AGT AAG TGC C-3′,
antisense 5′-TCT ATG AAG CCT TGG TTG CCC-3′;
IL-2Rb chain (506 bp) sense 5′-CGT AGG GTA AAG
ACC TGC GAC TTC-3′, antisense 5′-GGG ATG TGG
CAC TTG AGA ACT G-3′; IL-2Rc chain (355 bp) sense
5′-TGA CTT CTA CAG CCC CTG AAC ACC-3′, an-
tisense 5′-AGA TTT TCT GGA GCC CGT GG-3′; and
GAPDH (430 bp product) sense 5′-ATC ACT GCC ACC
CAG AAG ACT G-3′, antisense 5′-CCC TGT TGC TGT
AGC CGT ATT C-3′.
Overexpression of c-FLIP in TECs
Full length murine cFLIP-L cDNA, was generously
provided by Dr. J. Tschopp (University of Lausanne,
Switzerland). It was subcloned into a modified herpes
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simplex virus (HSV) expression vector (pHEX6300)
[18], which contains a zeocin-resistance gene (zeo) and
green fluorescence protein (GFP) to allow sorting. Mono-
layers of CS3.7 TECs were transfected with either
pHEX6300 vector or the vector containing the insert of
c-FLIP-L cDNA (pHEX6300-FLIP) by Lipofectamine
2000 (Invitrogen-Gibco) following the manufacturer’s
protocol. The stably transfected cell lines using either
empty vector pHEX6300 (CS3.7-6300) or pHEX6300-
FLIP (CS3.7-FLIP) were grown under antibiotic selec-
tion (zeocin) and sorted by GFP expression before pas-
saging. GFP expression was stable in multiple passages,
and more than 95% of cells used for experiments showed
strong green fluorescence by either flow cytometry or
microscopy.
Flow cytometric analysis (FACS)
TECs were released from culture plates by a brief
incubation with trypsin-ethylenediaminetetraacetic acid
(EDTA) solution (Sigma-Aldrich, St. Louis, MO, USA).
For analysis of surface protein expression, the cells were
incubated with antitarget antibody (anti-Fas or CD25
antibodies) conjugated with fluoroscein isothiocyanate
(FITC) (BD PharMingen) in phosphate-buffered saline
(PBS) containing 10% normal goat serum at 4◦C for 30
minutes, then washed with PBS twice. For apoptosis assay
by FACS, the cells were incubated with annexin-V conju-
gated with FITC in 1 × binding buffer (BD PharMingen)
for 15 minutes, in which apoptotic cells were identified
by annexin-V-FITC staining. The density of fluorescein
binding on the cell was measured by a flow cytometry and
analyzed by CellQuest software (BD Bioscience, Missis-
sauga, Ontario, Canada). Thin line indicated the back-
ground staining.
DNA fragmentation analysis
DNA fragmentation is a specific feature of apopto-
sis. Ligation-mediated PCR (LM-PCR) was used to visu-
ally determine the level of DNA fragments in apoptotic
cells following the manufacturer’s protocol (Clontech,
Mississauga, Ontario, Canada). Briefly, genomic DNA
from TEC cultures was isolated using Genomic DNA
Isolation kit (Trevigen, Gaithersburg, MD, USA). The
pure DNA (0.5 lg) was mixed with ligation buffer and
heated at 55◦C for 10 minutes, followed by incubation
with T4 DNA ligase at 16◦C for 16 hours. DNA fragments
were amplified using PCR with Taq DNA polymerase
(26 cycles) and visualized in 1% agarose in Tris-acetate-
EDTA (TAE) buffer containing 0.5 lg/mL ethidium bro-
mide.
Northern blot and RT-PCR
Expression of mRNA was analyzed by Northern blot
or RT-PCR. Total RNA was isolated from TEC cultures
using TRI reagent (Sigma-Aldrich) following the pro-
vided protocol. The level of total c-FLIP mRNA was
analyzed by Northern blot. Twenty-five micrograms of
loaded RNA was separated by 1.5% agarose in phos-
phate buffer and transferred onto nylon membrane.
Detection used c-FLIP cDNA probes prepared by
random-primer labeling (Stratagene, Cedar Creek, TX,
USA). The blot was reprobed with GAPDH cDNA to
control for mRNA loading. RT-PCR kits were used to
determine IL-2R mRNA following the provided protocol
(Invitrogen-Gibco). Briefly, 2 lg of total RNA were used
in RT, followed by PCR amplification (28 to 35 cycles) of
the target using appropriate primers and annealing tem-
perature. PCR products were visualized in 1% agarose in
TAE buffer containing 0.5 lg/mL of ethidium bromide.
Analysis of levels was semiquantitative with comparison
to GAPDH mRNA.
Western blot
Total protein expression was determined using West-
ern blots by standard methods. Briefly, whole cell lysates
were collected in lysis buffer [10 mmol/L Hepes (pH
7.9), 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L
ethyleneglycol tetraacetate (EGTA), 0.1% NP 40,
1 mmol/L dithiothreitol (DTT) and complete protease
inhibitor cocktail] (Roche, Mannheim, Germany). These
were mixed with 2 × sodium dodecyl sulfate (SDS) sam-
ple buffer [20 mmol/L Tris-HCl (pH 6.8), 5% (wt/vol)
SDS, 10% (vol/vol) mercaptoethanol, 2 mmol/L EDTA,
and 0.02% bromophenol blue] and boiled for 5 min-
utes. The protein content of each cell lysate was de-
termined by Bio-Rad assay (Bio-Rad Laboratories,
Hercules, CA, USA). One-hundred fifty micrograms
of total protein from each sample was fractionated by
10% SDS-polyacrylamide gel electrophoresis (PAGE)
and transferred to nitrocellulose membranes (Bio-Rad),
blocked with 5% Carnation fat-free milk in Tris-buffered
saline Tween-20 (TBS-T) for 1 hour, and then probed
with the appropriate antibodies in TBS containing 2.5%
of milk at 4◦C overnight. The specific protein binds
recognized by the antibodies on the membrane were
visualized by enhanced chemiluminescence (ECL) as-
say (Amersham Pharmacia Biotech, Buckinghamshire,
England). Blots were reprobed using anti nonphospho-
rylated extracellular-regulated protein kinase (ERK1/2)
monoclonal antibody (Stressgen) or anti-b-actin IgG
(Sigma-Aldrich) to confirm equal protein loading. In
some experiments, determination of differences in bands
was determined by a densitometry.
Statistical analysis
Comparisons between groups were performed using
analysis of variance (ANOVA) or t test as appropriate
using Statview 5.0 (SAS, Cary, NC, USA) on a Macintosh
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computer. P values of less than 0.05 were considered sig-
nificant. Values are expressed unless otherwise indicated,
as mean ± SD.
RESULTS
IL-2 and IFN-c induce murine TEC apoptosis
In previous work, we have demonstrated that pro-
inflammatory cytokines such as IFN-c and TNF-a can
induce apoptosis in cloned or primary TECs through a
Fas/FasL dependent mechanism [14]. A previous report
has also shown that human proximal tubular cells can
express high-affinity IL-2 receptors which regulate the
production of complement component C3 found during
renal inflammation [19]. While apoptosis in TECs has
not been a prominent feature following IL-2 exposure
in vitro, previous studies have used serum supplements
which contain multiple factors with potential antiapopto-
sis capacity. Therefore, a direct role for IL-2 in TEC injury
has not been excluded. As IL-2 can be found both in re-
nal allografts early posttransplant as well as in various
forms of autoimmune nephritis, we tested whether IL-2
had an effect on TEC apoptosis in the absence of serum
for 24 hours [20–22]. CS3.7 monolayers were treated with
5 to 20 ng/mL of IL-2 or with 10 ng/mL of IFN-c for
24 hours in serum-free media, and analyzed for apopto-
sis by FACS with annexin-V as well as by LM-PCR for
DNA fragmentation. TECs were examined at confluence
to exclude an effect of IL-2 related to TEC prolifera-
tion. The removal of serum and factors from confluent
monolayers with growth arrest also allowed comparison
of TEC effects between experiments. While cell morphol-
ogy did not change with IL-2 at 24 hours, cells assumed an
apoptotic appearance at later time points (48 hours) (not
shown). More important, early apoptosis prior to overt
cell death could be demonstrated by both annexin V la-
beling and DNA fragmentation. As shown in Figure 1A,
apoptosis increased in CS3.7 from 10.2 ± 2.2% in un-
treated cultures to 34.3 ± 5.2% in IL-2–treated cultures
by 24 hours. This level was equivalent to apoptosis in IFN-
c–treated cultures (38.3 ± 4.8%). Similar results were
noted in primary TEC culture (less than two passages),
with apoptosis increasing from 8.7 ± 1.5% to 27.2 ± 2.3%
and 30.5 ± 3.0%, respectively, in IL-2– and IFN-c–treated
cells. The induction of TEC apoptosis by IL-2 was also
concentration-dependent, with apoptosis noted at 5 ng/
mL and maximal in cultures treated with 20 ng/mL of IL-
2 (Fig. 1B). Taken together, these data demonstrate that
both cloned and nontransformed TEC in primary cul-
tures are sensitive to IL-2 effects. Similarly, both CS3.7
and primary culture cells respond to IFN-c to induce “self
injury” [14]. To further confirm the proapoptotic effects
of IL-2, cytokine treated CS3.7 were examined for DNA
fragmentation by LM-PCR, a sensitive and quantifiable
method of apoptosis detection. As shown in Figure 1C,
IL-2 increased the amount of DNA fragmentation. As
serum removal can induce apoptosis in many cell types
[23, 24], it is not surprising that some apoptosis was noted
as well in media controls. Indeed in the presence of serum
(10%), baseline levels of apoptosis in CS3.7 cells are usu-
ally less than 6% [14]. However, these data clearly indi-
cate that IL-2 as well as IFN-c can augment apoptosis by
24 hours in TECs growing in serum-free media.
Although described in human cells, the expression of
functional surface receptors for IL-2 has not been previ-
ously shown in murine proximal tubular cells. However,
TEC apoptosis in response to exogenous IL-2 suggest
they too have functional IL-2R. To confirm this, conflu-
ent monolayers of CS3.7 TECs were treated with IL-2
(20 ng/mL) or IFN-c (10 ng/mL) for 24 hours, and as-
sessed for a, b , and c IL-2R chains mRNA expression
by RT-PCR. As shown in Figure 2A, mRNA for IL-2Ra
chains was detected at basal conditions. Interestingly IL-
2R expression increased with IL-2, and expression of a, b ,
or c chains was easily detected only in IL-2–treated TEC.
In contrast IFN-c had no or less effect on IL-2R levels sug-
gesting the effect of IFN-c on apoptosis was independent
of the IL-2 axis. Similar results for expression of IL-2R
mRNA were observed using primary culture TECs iso-
lated from C3H-HeJ mice (data not shown). To confirm
the surface expression of high-affinity IL-2R, cytokine-
treated CS3.7 were labeled using an antibody specific for
the high-affinity IL-2 receptor (CD25, IL-2Ra). As illus-
trated in Figure 2B, surface expression of IL-2R (a chain)
by flow cytometry was also maximally increased by treat-
ment with IL-2, although a modest increase appeared to
occur with IFN-c as well.
IL-2–induced apoptosis in TECs is associated with
caspase-8 activation
Apoptosis of TECs in response to the proinflamma-
tory cytokines IFN-c and TNF-a occurs by a mechanism
of TEC self injury we have recently described, which in-
volves surface expression of Fas-FasL [14]. Therefore, to
exclude an effect of IL-2 on the expression of Fas and
FasL, CS3.7 TECs were treated with cytokines for 24
hours and tested by FACS. As illustrated in Figure 3A, the
surface expression of Fas protein on TECs did not change
with IL-2 as compared to control cultures (5.4 ± 2.2% vs.
5.1 ± 0.4%), whereas the levels of Fas expression on the
surface in IFN-c–treated cells increased to 30.8 ± 5.2%
in 24 hours. A lack of effect of IL-2 on Fas or FasL ex-
pression was also confirmed by Western blot. As shown
Figure 3B, Fas protein was unchanged in IL-2–treated
cells while Fas protein level was markedly up-regulated
by the treatment of IFN-c, consistent with our previous
data in TECs [14]. While IL-2 can alter ERK activa-
tion leading to phosphorylation [25], nonphosphorylated
ERK expression does not change with treatment and was
Du et al: c-FLIP regulates TEC apoptosis 1401
0
60
100 101 102 103 104
8.7 ± 1.5
MediumA
0
80
100 101 102 103 104
M1
38.3 ± 4.8*
0
80
100 101 102 103 104
M1
34.3 ± 5.2*
0
80
100 101 102 103 104
M1
10.2 ± 2.2
M1
0
60
100 101 102 103 104
M1
27.2 ± 2.3*
IL-2
0
60
100 101 102 103 104
M1
30.5 ± 3.3*
IFN-γ
Annexin-V-FITC
0
100
100 101 102 103 104
M1
13.50 ± 2.20
Medium
0
100
100 101 102 103 104
M1
16.30 ± 3.50
5 ng/mL IL-2
0
100
100 101 102 103 104
M1
33.58 ± 3.34*
20 ng/mL IL-2
0
100
100 101 102 103 104
M1
24.48 ± 5.12*
10 ng/mL IL-2
Annexin-V-FITC
B
− + −
−
IL-2
IFN-γ − +
C
Fig. 1. Interleukin (IL)-2 induces apoptosis in tubular epithelial cells (TECs). Primary or CS3.7 TEC monolayers were treated with cytokines [IL-2
or interferon-c (IFN-c)] in serum/growth factor-free medium for 24 hours. (A) Apoptotic cells induced by either 20 ng/mL of IL-2 or 10 ng/mL
of IFN-c were analyzed by FACS using annexin-V-fluorescein isothiocyanate (FITC). ∗P < 0.05 vs. medium controls. Primary TECs isolated from
C3H-HeJ mice (top panel). Cloned CS3.7 TECs (bottom panel). Data are presented as mean ± SD of triplicate samples and is representative of
three separate experiments. (B) The dose-dependent apoptosis of TECs in IL-2 (5 to 20 ng/mL)–treated cultures, analyzed by FACS using annexin-
V-FITC. ∗P < 0.05 vs. medium controls. Data are presented as mean ± SD of triplicate samples and is representative of three separate experiments.
(C) Apoptosis was determined by level of genomic DNA fragmentation using ligation-mediated-polymerase chain reaction (LM-PCR). Data are
representative of three separate experiments.
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Fig. 2. Interleukin (IL)-2 up-regulates IL-2 receptor (IL-2R) expression in tubular epithelial cells (TECs). CS3.7 monolayers were treated with
either 20 ng/mL IL-2 or 10 ng/mL interferon-c (IFN-c) in serum/growth factor-free medium for 24 hours. (A) Levels of mRNA for a, b , or c chains
of IL-2R were analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was used to control for amount of RNA used in each sample. Two separate experiments were performed. (B) Surface expression of IL-2R
a chain (CD25) was analyzed using FACS with anti-CD25 antibody as compared to control antibody (thin line). ∗P < 0.05 vs. medium controls.
Data are presented as mean ± SD of triplicate samples and are representative of three separate experiments.
used here to control for protein loading. As the Fas death
signal pathway is mediated by caspase-8 following re-
cruitment of procaspase-8 to the DISC, we tested for the
activation of caspase-8 by IL-2 and IFN-c using Western
blot analyses. Following incubation with IL-2 (20 ng/mL)
or IFN-c (10 ng/mL) in media without serum, procaspase-
8 decreased by 11/2 hours with IFN-c and 5 hours
with IL-2, suggesting both can activate caspase-8 but
with different kinetics (Fig. 4). Furthermore, the addi-
tion of z-IETD-fmk, a specific inhibitor of caspase-8, pre-
vented apoptosis in IL-2– or IFN-c–treated TEC cultures
supporting the role of caspase-8 activation in apoptosis.
Apoptosis in IL-2–treated TEC cultures decreased from
40.2 ± 2% in IL-2–treated cultures without inhibitor to
12.2 ± 3% in cultures with z-IETD (P < 0.05) (Fig. 5A),
levels that were close to baseline unstimulated TECs.
Similar inhibition was noted in IFN-c–treated cultures
and apoptosis decreased to 19.5 ± 4% with z-IETD from
49.5 ± 2.6% in cytokine-treated cultures (P < 0.05). The
level of apoptosis (15 to 22.6%) in untreated TECs rep-
resent the result of serum removal during the 24 hours of
culture.
We have previously shown that Fas-mediated fratri-
cide of TECs in response to INF-c and TNF-a is related
to enhanced Fas expression and activation of caspase-8.
While IL-2 had no effect on Fas expression, an effect
of IL-2 on Fas-mediated activation of caspase-8 was not
excluded. Therefore, IL-2 was tested using Fas-deficient
TECs (M3.1-lpr). In contrast to wild-type TECs, IL-2
(20 ng/mL for 24 hours) did not induce apoptosis of
M3.1-lpr cells (3.18 ± 1.20% compared to 1.59 ± 0.20%
in untreated cultures) (Fig. 5B). These data suggest IL-
2–induced apoptosis of TECs occurs by regulation of
caspase-8 activity to allow Fas-mediated apoptosis.
TECs express c-FLIP which inhibits apoptosis
and is down-regulated by IL-2
c-FLIP, including the long form of c-FLIP (c-FLIP-L),
is considered to be a key endogenous inhibitory protein
for caspase-8 activation in several cell types, including
lymphocytes and endothelium [10]. The expression of c-
FLIP has been noted in renal carcinoma cells but not in
highly differentiated murine proximal TECs. As shown
in Figure 6, c-FLIP is expressed in kidney cortex as well
as primary TECs taken from the parental strain C3H-
Hej mice (Fig. 6A) and cloned CS3.7 TECs (Fig. 6B and
C). Interestingly, c-FLIP-L is primarily expressed in renal
cortex which is >75% tubular epithelium, while cultured
TECs (primary and cloned) express both c-FLIP-L and
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Fig. 3. Interleukin (IL)-2 does not alter Fas or FasL expression in tubular epithelial cells (TECs). CS3.7 monolayers were incubated in the absence
or presence of 20 ng/mL of IL-2 or 10 ng/mL of interferon-c (IFN-c) in serum/growth factor-free medium for 24 hours. (A) Fas expression on
the surface of TECs was analyzed by FACS with anti-Fas-fluorescenin isothiocyanate (FITC). ∗P < 0.05 vs. medium controls. Data are presented
as mean ± SD of triplicate samples and are representative of three separate experiments. (B) Total Fas or FasL proteins (48 kD or 38 kD) were
analyzed by Western blot. Extracellular-regualted protein kinase (ERK)1/2 (42/44 kD) were used as control for protein content in each sample.
Data are representative of three experiments.
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Fig. 4. Cytokines [interleukin (IL)-2 or interferon-c (IFN-c)] activate
procaspase-8 in tubular epithelial cells (TECs). CS3.7 cells were stimu-
lated with IL-2 (top panels) or IFN-c (bottom panels) in serum/growth
factor-free medium. Procaspase-8 protein (55 kD) was identified using
anticaspase-8 antibody in Western blot. ERK1/2 proteins were used as
protein loading control. Data are representative of three experiments.
the shorter processed FLIP-43 kD form. This may be re-
lated to culturing and a requirement for processing of
FLIP to maintain homeostasis and prevent apoptosis in
monolayers in vitro. Importantly, c-FLIP was largely re-
duced in TECs treated with IL-2 for 24 hours, while IFN-c
had no effect on FLIP mRNA levels (Fig. 6B). Similarly,
by Western blot using a monoclonal antiboy that recog-
nizes the major isoforms of c-FLIP in mammalian cells,
55 and 43 kD c-FLIP proteins noted in unstimulated cells
were reduced with IL-2 while no changes were seen in
c-FLIP proteins in IFN-c–treated cultures (Fig. 6C). Spe-
cific bands were assessed by densitometry and levels were
calculated as a ratio to b-actin levels to control for protein
loading. c-FLIP-L (55 kD) in media controls (0.54 and
0.52, lanes 1 and 2) were not decreased by IFN-c (0.45
and 0.56, lanes 3 and 4) at 48 hours, but were markedly
reduced by IL-2 (0.38 and 0.15, lanes 5 and 6). Similarly
c-FLIP-43 kD, a product of c-FLIP-L processing was not
decreased by IFN-c (1.45 and 1.48) compared to media
control (1.67 and 1.44), but was markedly reduced by IL-2
(0.89 and 0.38). Similar decreases but more modest were
noted at 24 hours (not shown).
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Fig. 5. Addition of caspase-8 inhibitor
(z-IETD-fmk) or Fas deficiency prevents
cytokine-induced apoptosis in tubular
epithelial cells (TECs). (A) CS3.7 TEC
monolayers in serum/growth factor-free
medium were treated with either 20 ng/mL
interleukin (IL)-2 in the absence or pres-
ence of 50 lmol/L inhibitor, or 10 ng/mL
interferon-c (IFN-c) in the absence or
presence of 100 lmol/L inhibitor for 24 hours.
Cultures were pretreated with the inhibitor
for 3 hours, followed by stimulation with
cytokines. Apoptotic cells were identified
by annexin-V-fluorescein isothiocyanate
(FITC) and analyzed by FACS. ∗P < 0.01 vs.
cultures pretreated with inhibitor or medium
controls. Data are presented as mean ± SD of
triplicate samples and are representative of
three separate experiments. (B) Fas-deficient
M3.1-lpr TEC monolayers were treated
with 5 to 20 ng/mL IL-2 in serum/growth
factor-free medium for 24 hours. Apoptotic
cells were identified by annexin-V-FITC and
analyzed by FACS (no statistical significance
was found between treatment and control
groups). Data are presented as mean ± SD
of triplicate samples and are representative
of three separate experiments.
These data suggest that while both IL-2 and IFN-c can
induce apoptosis and activate caspase-8, they do so by
different mechanisms. IFN-c may cause caspase-8 acti-
vation by augmenting surface Fas expression and activa-
tion through augmented interaction with FasL on adja-
cent TECs as we have described [14]. Alternatively, IL-2
appears to down-regulate of c-FLIP in TECs, a major in-
hibitor of caspase-8. While there may be a subtle direct ef-
fect on activation of caspase-8 leading to TEC apoptosis,
it is more likely that loss of c-FLIP enhances TEC sus-
ceptibility to death receptor signaling through caspase-
8. Therefore, to test whether IL-2 down-regulation of
c-FLIP in TECs increased susceptibility to death receptor
(Fas and TNF-R)–mediated apoptosis, IL-2 primed CS3.7
TECs were treated with IL-2 and then incubated with
1 lg/mL of anti-Fas IgG or 10 ng/mL TNF-a in serum-
free K1 media for 48 hours. The greatest increase in apop-
tosis occurred in TECs primed with IL-2 and exposed to
TNF-a (P < 0.05) (Table 1). Interestingly, there was no in-
crease in apoptosis in IL-2 primed cells using anti-Fas IgG
(43.1 ± 11% vs. 39.1 ± 10%) at 48 hours, although the
high level of apoptosis induced by this antibody or the
48-hour period of treatment could have missed earlier ef-
fects by IL-2. Therefore, to confirm a key role for c-FLIP
protection in response to cytokines, we expressed trans-
genic c-FLIP-L in CS3.7 TECs. After stable transfection
of TECs with c-FLIP-L (CS3.7-FLIP) or empty vector
(CS3.7-6300), c-FLIP-L protein levels were examined by
Western blot. As illustrated in Figure 7, the level of c-
FLIP-L and c-FLIP-43 kD protein in CS3.7-FLIP TECs
was abundantly expressed compared to that of parental
CS3.7 or control vector transfected CS3.7-6300 cells, and
was maintained following IL-2 exposure (not shown).
Monolayer cultures of CS3.7-FLIP and CS3.7-6300 were
treated with 20 ng/mL of IL-2 or 10 ng/mL of IFN-c
as described. Apoptosis was induced in response to cy-
tokines was tested with these cells (Table 2). CS3.7-FLIP
TECs were able to resist apoptosis with both IL-2 and
IFN-c. Similarly, induction of apoptosis was completely
blocked in response to anti-Fas IgG or TNF-a in CS3.7-
FLIP TECs as compared to CS3.7-6300 (not shown).
Overall levels of apoptosis were reduced in untreated
and treated cells in pHEX transfected cells as compared
to parental CS3.7 TECs. It is of note that c-FLIP was
increased slightly in stable empty vector CS3.7-6300 to
account for this difference. It is possible that antibiotic
selection and enrichment of TECs by FACS sorting may
have resulting in a bias toward higher c-FLIP (or other
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survival protein) levels in surviving cells. Alternatively,
the GFP may have had an effect on apoptosis. However,
as CS3.7-6300 and CS3.7-FLIP TECs were isolated and
treated under the same conditions that may have led to
such selection bias, CS3.7-6300 TECs provide a valid con-
trol for apoptosis experiments using CS3.7-FLIP. Impor-
tantly, levels of c-FLIP were clearly higher in CS3.7-FLIP
TEC as well as resistance to apoptosis, supporting a key
role for c-FLIP in regulating caspase-8–mediated apop-
tosis in TECs. Further support of this was the effect of c-
FLIP overexpression on inhibiting caspase-8 activation.
As demonstrated in Figure 8, procaspase-8 levels were
unchanged in CS3.7-FLIP following exposure to IL-2 or
IFN-c. Densitometry was used to quantify differences.
The relative density of procaspase-8 was unchanged in
IL-2–treated TECs at 2 hours (0.61) and 5 hours (0.66),
and was also not changed with IFN-c at 11/2 years (0.61)
and 3 hours (0.65) as compared to untreated cells (0.65).
In marked contrast and as noted in the parental CS3.7
TECs, procaspase-8 levels were decreased in CS3.7-6300
with either IL-2 at 2 hours (0.62) and 5 hours (0.31), and
with IFN-c at 11/2 years (0.25) and 3 hours (0.18).
DISCUSSION
Given the potentially lethal consequences of indis-
criminant binding to death receptors, regulatory “check
points” in caspase activation must exist in most cells.
TECs by their capacity to express both Fas and FasL may
be particularly vulnerable to apoptosis, and we have re-
cently demonstrated that TECs can commit cell contact
self injury or death, which requires the expression and ap-
position of FasL expressing TECs with Fas bearing TECs.
As proinflammatory cytokines such as IFN-c and TNF-
a are invariably found during renal inflammation, TECs
might be expected to express endogenous inhibitors of
apoptosis as a means of protection. It is worthwhile not-
ing that human renal carcinoma cells express c-FLIP to
resist death following chemotherapy and so cancerous
cells may exploit endogenous mechanisms of protection.
In the present study we have demonstrated renal cortex,
primary culture TECs and cloned TECs express c-FLIP,
and thus this protein likely has a primary role in protect-
ing normal epithelium in the kidney during inflammation.
While c-FLIP was initially described as a key regu-
lator of Fas-mediated apoptosis in T cells [26], its role
may be more extensive as c-FLIP is also found in nor-
mal endothelium and cardiac tissue. Until the present
study, c-FLIP expression has not been described in nor-
mal TECs [27–31], and thus c-FLIP may be a general
mechanism in many cell types to control caspase-8 ac-
tivation. Its expression in TECs is particularly notable
as unlike most cells, TECs express both Fas and FasL,
and require robust mechanisms of self preservation dur-
ing inflammation. Although its mechanism of action has
not been completely elucidated, c-FLIP is a mammalian
caspase-8 homologue which has been suggested to act in
a “dominant-negative” manner to generate a nonfunc-
tional tetrameric complexes to prevent Fas and TNF-R1
apoptosis [31]. Nearly identical in structure to caspase-
8, c-FLIP contains two-linked DEDs but lacks the con-
served pentapeptide QAC(R/Q)G essential to cysteine
protease catalysis [32, 33]. c-FLIP is expressed as four
main mRNA splice variants and two forms, namely c-
FLIP-short and c-FLIP-L, are expressed in human tissues
[29, 33, 34]. All isoforms bind to the DED of FADD and
caspase-8 as well as to caspase-10, and the TNFR1/2 sig-
naling proteins TRAF1 and TRAF2 [34, 35]. It has been
suggested that both caspase-8 and c-FLIP-L are simulta-
neously recruited to the DISC, where c-FLIP-L is cleaved
into a p43 intermediate form [27] and it may be that the
p43 intermediate form of c-FLIP remains in the DISC
to interrupt caspase-8–initiated apoptosis. We observed
a prominent expression of the p43 intermediate form of
c-FLIP in TECs under basal conditions in vitro and it may
be that c-FLIP-L is routinely cleaved in culture conditions
in murine TECs to the intermediate form following inter-
action with FADD. Interestingly c-FLIP-L is the primary
form in renal cortex rather than the p43 form, suggesting
under nonstress conditions in vivo, c-FLIP-L processing
is not prominent.
Initially, both proapoptotic [34] and antiapoptotic [36]
effects for c-FLIP were proposed but data from cells sta-
bly overexpressing c-FLIP and from mice deficient in
c-FLIP clearly supports an antiapoptotic function [37].
The biology of c-FLIP is complex as it can act in vitro as
a molecular switch between cell death and growth sig-
nals transmitted by the death receptor Fas (CD95). T
cells from transgenic mice that overexpress c-FLIP-L in
the T-cell compartment (c-FLIP-L transgenic mice) re-
sist FasL-induced apoptosis. In contrast stimulation of c-
FLIP transgenic T lymphocytes with suboptimal doses
antigen leads to increased proliferative responses [38].
Initial studies of c-FLIP expression in T cells suggested
that it may be regulated by cytokines such as IL-2. How-
ever, while initial studies indicated that IL-2 enhanced
apoptosis in CD4+ T cells was associated with down-
regulation of c-FLIP mRNA [26], this was subsequently
found to be related to cell cycle and altered levels in G1/S
transition [39]. The cloned CS3.7 TECs we used in the
present study are highly differentiated proximal tubular
cells that exhibit contact inhibition, as do the primary cul-
tured TECs we studied. As all analyses were performed
on TECs taken from confluent monolayers with removal
of growth factors and serum in media prior to exposure to
cytokines, it is unlikely that further proliferation of TECs
or cycling of cells played a role in the reduced c-FLIP
levels noted in IL-2–treated TECs.
The down-regulation of c-FLIP by IL-2 in intact TECs
with resultant apoptosis may have significant implications
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Fig. 6. c-FLIP expresses in kidney cortex and cultured tubular epithe-
lial cells (TECs) and is down-regulated by interleukin (IL)-2. (A) c-
FLIP protein was identified by Western blot in homogenized kidney
cortex (lanes 1 and 2) and primary TECs (two passages) (lanes 3 and
4) from naı¨ve C3H-HeJ mice. For the regulation of c-FLIP expression
by cytokines, CS3.7 TEC monolayers were incubated with 20 ng/mL
IL-2 or 10 ng/mL interferon-c (IFN-c) in serum/growth factor-free
medium for 24 hours. (B) c-FLIP mRNA levels were analyzed by North-
ern blot and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was used to control for amount of RNA loaded in each lane.
(C) c-FLIP proteins (55 and 43 kD) were determined by Western blot.
b-actin protein was used to control for protein content in each sample.
Data are representative of three experiments.
Table 1. Pretreatment with interleukin (IL)-2 increases tumor
necrosis factor-a (TNF-a) in tubular epithelial cells (TECs)
Primed Treatment Apoptosis
Medium Medium 8.0 ± 2.4
Medium TNF-a 14.3 ± 5.7
Medium Anti-Fas 39.1 ± 11
IL-2 Medium 15 ± 5
IL-2 TNF-a 22.3 ± 7a
IL-2 Anti-Fas 43.0 ± 11
CS3.7 cells were primed with 20 ng/mL IL-2 in K1 medium for 24 hours,
followed by stimulation with 10 ng/mL TNF-a or 1 lg/mL anti-Fas antibody in
serum and growth factor–free K1 medium for 48 hours. Apoptotic cells were
analyzed by FACS with annexin-V-fluorescein isothiocyanate (FITC). Data are
presented as mean ± DS of five separate experiments.
aP < 0.05 vs. TNF-a–treated cultures or medium controls.
55 kD
43 kD
c-FLIP
ERK 1/2
1 2 3
Fig. 7. c-FLIP protein level is elevated by stable c-FLIP cDNA trans-
fection in tubular epithelial cells (TECs). CS3.7 TECs were stably trans-
fected with empty vector (CS3.7-6300) or vector containing c-FLIP-
L cDNA (C3.7-FLIP). Protein levels of c-FLIP (55 and 43 kD) in
parental CS3.7 (lane 1), CS3.7-6300 (lane 2), or CS3.7-FLIP (lane 3)
were determined by Western blot. Extracellular-regulated protein ki-
nase (ERK)1/2 protein was used to control for protein content in each
sample. Results are representative of two separate analyses.
for renal inflammation associated with IL-2 expression
and as well for therapy with IL-2 systemically. Indeed,
tubular dysfunction with elevated serum creatinine ne-
cessitated the discontinuation of high-dose IL-2 therapy
in several clinical trials [40–43]. TECs may also be ex-
posed to IL-2 during diverse forms of renal inflammation
which involves infiltrating T cells. In addition, intragraft
IL-2 mRNA can be found during acute renal transplant
rejection [44], although levels depend on the methodol-
ogy used and timing of samples [45, 46]. It is interest-
ing to consider that anti-CD25 monoclonal antibodies
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Table 2. Overexpression of c-FLIP prevents cytokine-induced
apoptosis in tubular epithelial cells (TECs)
Interleukin-2 +
Treatment Medium Interleukin-2 Interferon-c interferon-c
CS3.7-FLIP 6.6 ± 1.3 5.7 ± 2.7 6.9 ± 4 7.2 ± 2.7
CS3. 7-6300 4.1 ± 0.3 9.1 ± 3.7a 9.2 ± 2.5a 11.4 ± 2.6a
Stably transfected TECs (CS3.7-FLIP and CS3.7-6300) were treated with 20
ng/mL interleukin (IL)-2 and/or 10 ng/ML interferon-c (INF-c) in serum and
growth factor-free K1 medium for 24 hours. Apoptotic cells were identified by
annexin-V-phycoerythrin (PE) and analyzed by FACS. Data are presented as
mean ± SD of five separate experiments.
aP < 0. 05 vs. medium controls.
which are extensively used clinically in renal transplants
for prophylactic effects on T-lymphocyte activation [47]
could provide an additional benefit for TEC survival in
patients with delayed graft function [48]. Significant uri-
nary expression of IL-2 is also found in patients with ac-
tive lupus nephritis [22]. Despite these numerous stud-
ies, the response of TECs to IL-2 has not been exten-
sively investigated. Human proximal TECs express func-
tional IL-2 receptor and exposure to IL-2 increases C3
complement [19] and adenylate cyclase [49]. In contrast
to our study, which showed up-regulation of high-affinity
IL-2 receptor mRNA in murine TECs with IL-2 but not
IFN-c, and apoptosis with IL-2, IL-2R on human TECs
was up-regulated by IFN-c and apoptosis was not found
following IL-2 exposure. While this may suggest some
species specific differences exist, we did note a modest
increase in IL-2R surface expression with IFN-c. As well,
differences in culture conditions may explain differences
in results. Apoptosis studies with human TECs following
IL-2 in vitro may have been affected by the antiapop-
tosis factors contained in serum used, such as vascular
endothelial growth factor (VEGF). Consistent with this,
we have noted lower levels of apoptosis in murine TECs
grown in serum, and removal of serum and growth factors
from media in the present experiments were to isolate the
effect of cytokines tested as well as prevent further pro-
liferation of TECs.
The mechanism by which IL-2 regulates c-FLIP expres-
sion in TECs is not known. Signaling pathways that regu-
late c-FLIP in other cells depends on cell type. c-FLIP ex-
pression is regulated by mitogen-activated protein kinase
kinase (MAPKK) in T lymphocytes [50] and by phos-
phatidylinositol 3 kinase other cell types [51]. In addi-
tion, Yang et al (2003) have shown calcium/calmodulin-
dependent protein kinase II regulates c-FLIP expression
in malignant glioma cells [52]. Interestingly IL-2R share
common beta and gamma chains with IL-15R [53] which
is constitutively expressed in normal tubular epithelial
cells. In contrast to the proapoptotic effects of IL-2, IL-
15 acts as an autocrine survival factor for TECs. Consis-
tent with this observation is that apoptosis induced with
anti-Fas antibody is greater in IL-15−/− than in wild-type
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Fig. 8. Overexpression of c-FLIP prevents cytokine-induced activation
of procaspase-8 in tubular epithelial cells (TECs). TEC cultures (CS3.7-
FLIP, top panel; CS3.7-6300, bottom panel) in serum/growth factor-free
medium were stimulated with either 20 ng/mL of interleukin (IL)-2
for 2 or 5 hours, or 10 ng/mL of interferon-c (IFN-c) for 11/2 or 3
hours. Procaspase-8 levels were assessed using anticaspase-8 antibody
in Western blot. b-actin protein was used to control for protein content
in each sample. Data are representative of four experiments.
TECs. Therefore, engagement of members of the same
cytokine receptor family may lead to opposite effects on
TEC survival. It is possible that in vivo the final result
of IL-2 exposure in TECs may depend on the ability of
TEC to express a number of antiapoptotic proteins cy-
tokines such as IL-15 [54]. We have observed that CS3.7
TECs express a number of antiapoptosis proteins (IAP1
and IAP2) in response to VEGF stimulation at 24 hours
(our unpublished data) and thus TECs under some con-
ditions may utilize mechanisms of protection in addition
to c-FLIP.
Apoptosis with IL-2 and IFN-c in TECs was associ-
ated with the activation of caspase-8, an early “initiator”
caspase in the cascade following engagement of death re-
ceptors such as Fas. The major role of caspases in inducing
apoptosis is well-established [10, 55] but a role for IL-2 in
caspase-8 activation in TECs has not been previously de-
scribed. While our current study demonstrates that inhi-
bition of caspase-8 activity by specific synthetic inhibitors
(IETD) or by augmenting endogenous levels of c-FLIP-
L prevented both IL-2– and IFN-c–induced cell death,
the molecular events induced by these proinflammatory
cytokines leading to procaspase-8 cleavage within TECs
is unclear. IFN-c has been shown to directly up-regulate
procaspase-8 in tumor cells [52, 56] and it is possible that
IFN-c has a similar direct effect in murine TECs. How-
ever, given our recent observations regarding self injury
of TECs with IFN-c in association with increased surface
expression of Fas [14], it is likely that IFN-c has an indirect
effect as well through surface Fas expression and subse-
quent activation of caspase-8. In contrast, the mechanism
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for IL-2–induced apoptosis does not appear to be due to
increased expression of Fas. Indeed, our data show the
induction of apoptosis by IL-2 requires the expression of
Fas by TECs, suggesting that inhibition of FLIP permits
enhanced caspase-8 activation through Fas. As the reduc-
tion of c-FLIP protein did not occur until more than 12
hours post exposure to IL-2, while activation of caspase-
8 occurred in a shorter period of time (<5 hours), it is
likely that caspase-8 activation did not only occur as a
result of reduced c-FLIP. While these data may support
a direct effect for IL-2 on the activation of components
of the Fas-associated DISC (a complex of Fas, FADD,
and procaspase-8), further investigations are required.
However, these data do not exclude an important role
for c-FLIP down-regulation in TEC injury, in chronic in-
flammation.
CONCLUSION
IL-2 decreased mRNA and protein expression of c-
FLIP in murine TECs, an endogenous caspase-8 inhibitor
not previously described in normal renal epithelial cells.
c-FLIP expression was found in kidney cortex, primary
cultured TEC and cloned TEC, and inhibition of apop-
tosis with synthetic caspase-8–specific inhibitors or with
over expression of c-FLIP suggests this protein is likely a
key endogenous regulator of caspase-8–mediated apop-
tosis in vivo. This is the first report of c-FLIP and reg-
ulation by IL-2 in murine renal tubular epithelial cells.
Augmentation of c-FLIP in TECs may enhance an en-
dogenous mechanism by which TECs normally resist in-
jury to caspase-8–mediated apoptosis and thus may be
a useful and novel strategy to prevent tubular injury in
transplant rejection and autoimmune nephritis.
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